点击关注大松树,获取一手深度分析天风证券医药团队杨松/曹文清如您需要完整版报告,可联系天风证券医药团队或您对口销售报告摘要携手默沙东深耕TROP2ADC全球布局,具有BIC潜力芦康沙妥珠单抗(SKB264)是公司自主研发的一款靶向TROP2的ADC药物,海外权益已授权给默沙东。该药物目前已进入十多项实体瘤适应症的三期全球多中心注册临床研究阶段。根据默沙东规划,SKB264将在2027年迎来9项...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.